Document:

Exhibit 4.1

 

amendment
Agreement of Warrants to purchase

 

Common
Stock

 

This
amendment AGREEMENT of Warrants to Purchase common Stock (this “Agreement”) is made as of December 5,
2019, by and between Aevi Genomic Medicine, Inc., a Delaware corporation (the “Company”) and the undersigned
holders (each a “Holder” and collectively the “Holders”). The Company and the Holders are
sometimes referred to herein collectively as the “Parties” and individually as a “Party.”

 

RECITALS

 

WHEREAS, the Company
issued to the Holders those certain Warrants to Purchase Common Stock on October 17, 2017 (the “Warrants”),
which, among other things, entitle the Holders to purchase an aggregate of 3,953,904 shares of common stock, $0.0001 per value
per share of the Company (the “Warrant Shares”);

 

WHEREAS, the Warrants
were issued pursuant to that certain Securities Purchase Agreement, dated as of August 9, 2017, by and among the Company and the
purchasers identified therein (the “Purchase Agreement”);

 

WHEREAS, the Holders
are the holders of Warrants representing more than a majority of the Warrant Shares obtainable upon exercise of the Warrants currently
outstanding; and

 

WHEREAS, in accordance
with Section 16 of the Warrant, the Holders hereby wish to amend all outstanding Warrants (as more fully set forth below) concurrently
with entry into that certain Agreement and Plan of Merger (the “Merger Agreement”) by and between Cerecor, Inc.,
a Delaware corporation, the Company and certain other parties named therein.

 

NOW, THEREFORE,
in consideration of the mutual promises and covenants contained herein, the receipt and sufficiency of which are hereby acknowledged,
the Parties do hereby agree as follows:

 

AGREEMENT

 

1.       Definitions.
Any and all capitalized terms not specifically defined herein shall have the meanings ascribed to them in the Warrants.

 

 

    	 	1	 

     

    

 

2.       Amendment.
Section 9(c) is hereby deleted in its entirety and replaced with:

 

“If, at
any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the Company with or into another
Person, in which the Company is not the survivor or the stockholders of the Company immediately prior to such merger or consolidation
do not own, directly or indirectly, at least 50% of the voting securities of the surviving entity, (ii) the Company effects any
sale of all or substantially all of its assets or a majority of its Common Stock is acquired by a third party, in each case in
one or a series of related transactions, (iii) any tender offer or exchange offer (whether by the Company or another Person) is
completed pursuant to which all or substantially all of the holders of Common Stock are permitted to tender or exchange their shares
for other securities, cash or property, or (iv) the Company effects any reclassification of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property
(other than as a result of a subdivision or combination of shares of Common Stock covered by Section 9(a) above) (in any
such case, a “Fundamental Transaction”), then if this Warrant shall not have been exercised in full immediately
prior to such Fundamental Transaction, then this Warrant shall be deemed to be automatically exercised in a “cashless exercise”
pursuant to Section 10 below, notwithstanding whether there is an effective Registration Statement or current prospectus,
without further action on the part of the Holder (and the Holder hereof shall be deemed to be a holder of the Common Stock, if
any, issued upon such automatic exercise), immediately prior to the Fundamental Transaction and thereafter this Warrant shall be
null and void for all purposes. For the sake of clarity, whether or not Warrant Shares are issued to the Holder pursuant to the
“cashless exercise” formula in Section 10, this Warrant shall be null and void for all purposes immediately
prior to a Fundamental Transaction following its automatic “cashless exercise”. In the event that the Warrant is deemed
to be automatically exercised in connection with a Fundamental Transaction in accordance with the foregoing provision, the “Exercise
Date” of the Warrant for the purposes hereof shall be the date of the consummation by the Company of such Fundamental Transaction.”

 

3.       Termination.
This Agreement shall terminate automatically, without any notice or other action by any Party, upon the termination of the Merger
Agreement in accordance with its terms. In the event of the termination of this Agreement, this Agreement shall forthwith become
null and void, there shall be no liability on the part of any of the Parties, and all rights and obligations of each Party hereto
shall cease.

 

4.       Governing
Law. This Agreement and the Parties’ rights and obligations hereunder shall be governed by, and construed and interpreted
in accordance with, the laws of the State of New York, without regard to the principles of conflicts
of law thereof.

 

5.       Successors
and Assigns. This Agreement shall be binding upon, and inure to the benefit of, the Parties and their respective successors,
heirs and permitted assigns. No Party may assign its rights, duties or obligations under this Agreement without the prior written
consent of the other Parties.

 

6.       Counterparts.
This Agreement may be executed in any number of separate counterparts, all of which shall constitute one agreement. Execution and
delivery of this Agreement may be effected by pdf, facsimile, or other electronic transmission of signature pages.

 

7.       Amendments.
This Agreement may be amended, modified or waived only in a writing signed by each of the Parties hereto.

 

[Signature pages follow]

    	 	2	 

     

    

 

IN WITNESS WHEREOF, the
undersigned have executed this Amendment Agreement as of the date first written above.

 

 

	 	AEVI GENOMIC MEDICINE, INC.
	 	 
	 	 
	 	By: ____________________________________
	 	 
	 	Name: __________________________________
	 	 
	 	Title: ___________________________________

 

 

 

 

 

 

 

 

[Signature Page to Amendment Agreement
of Warrants to Purchase Common Stock]

     

     

    

 

	 	THE CHILDREN’S HOSPITAL OF 
	 	PHILADELPHIA FOUNDATION 
	 	 
	 	 
	 	By: ____________________________________
	 	 
	 	Name: __________________________________
	 	 
	 	Title: ___________________________________

 

 

 

 

 

 

 

 

 

 

 

 

[Signature Page to Amendment Agreement
of Warrants to Purchase Common Stock]

     

     

    

 

	 	____________________________________
	 	Sol J. Barer

 

 

 

 

 

 

 

 

 

 

[Signature Page to Amendment Agreement
of Warrants to Purchase Common Stock]

     

     

    

 

	 	____________________________________
	 	Eugene A. Bauer

 

 

 

 

 

 

 

 

 

[Signature Page to Amendment Agreement
of Warrants to Purchase Common Stock]

     

     

    

 

	 	____________________________________
	 	Michael F. Cola

 

 

 

 

 

 

 

 

 

 

 

 

[Signature Page to Amendment Agreement
of Warrants to Purchase Common Stock]

     

     

    

 

	 	____________________________________
	 	Alastiar Clemow

 

 

 

 

 

 

 

 

 

 

 

 

 

[Signature Page to Amendment Agreement
of Warrants to Purchase Common Stock]

     

     

    

 

	 	____________________________________
	 	Barbara Duncan

 

 

 

 

 

 

 

 

 

 

 

 

[Signature Page to Amendment Agreement
of Warrants to Purchase Common Stock]

     

     

    

 

	 	____________________________________
	 	Joseph J. Grano, Jr.

 

 

 

 

 

 

 

 

 

 

 

 

 

[Signature Page to Amendment Agreement
of Warrants to Purchase Common Stock]

     

     

    

 

	 	____________________________________
	 	Garry A. Neil

 

 

 

 

 

 

 

 

 

 

 

 

[Signature Page to Amendment Agreement
of Warrants to Purchase Common Stock]EXHIBIT 10.1

    

     

      

     
      	
              
                                                          Michael W. Lamach

                  

                                                          Chairman and Chief Executive Officer

                

                

              

            	
              
                
                  Ingersoll-Rand plc 

                  170/175 Lakeview Drive 

                  Airside Business Park 

                  Swords, Co. Dublin, Ireland

                

                 

            	
              U.S . Mailing Address

              800-E Beaty Street

              
                
                  
                    P.O. Box 940

                  

                

              

              Davidson, NC 28036

            

    

     

      

    
      
        
          
            

            

          

          

      

      December 5, 2019

      

      

      

      

      Mr. Chris Kuehn 

      

      

      

      

      Dear Chris:

       

      

      I am pleased to offer you the position of Senior Vice President and Chief Financial Officer reporting directly to me. This
        position will be located in Davidson, North Carolina and becomes effective as of the close of the transaction to separate the Industrial Segment, anticipated to be March 2, 2020. I look forward to your acceptance of this offer and the contributions
        you will make in this role.

      

      

      The following summarizes the impact of this new assignment on your compensation and benefits.

      

      

      
        
          
            
              	
                      1.

                    	
                      Your new base salary, effective as of the close of the transaction, will be set at an annual rate of $680,000 (Six Hundred Eighty Thousand U.S. dollars) paid monthly. This represents an increase of $170,000, or 33.3% above your
                        current base salary of $510,000. This increase is inclusive of your 2020 merit and you will next be eligible for merit in 2021.

                    

            

          

        

      

      

      

      
        
          
            
              	
                      2.

                    	
                      Your Annual Incentive Matrix (“AIM”) target opportunity will increase from 65% to 100% of your base salary. When you take into account your new base salary and your new AIM target, your annualized cash incentive target will
                        increase from $331,500 to $680,000 or by $348,500 (105.1%). The actual award that you may receive can range from 0% to 200% of the targeted amount depending upon your performance and the performance of the Company. For the 2020 plan
                        year, as long as the transaction closes prior to April 1st, your AIM target award
                        will be calculated with an effective date of January 1, 2020. If the transaction closes after April 1st, your 2020 AIM award will be prorated based on the date of the transaction.

                    

            

          

        

      

      

      

      
        
          
            
              	
                      3.

                    	
                      Effective as of the close of the transaction, your annual Long-Term Incentive (“LTI”) target will increase from $650,000 to $1,800,000 or by $1,150,000 (176.9%). Your LTI target value will be awarded in two parts:

                    

            

          

        

      

      

      

      
        
          
            
              	 	
                      ●

                    	
                      Stock Options and Restricted Stock  Units (“RSU”s): Your annual equity (stock option and RSU) target will increase from $325,000 to $900,000, or by $575,000. At this time, based on the projected transaction close date of March
                        2nd, it is anticipated that your updated equity target will be  used to determine your award  granted  in 2020 and will be

                    

            

             

            

          

        

      

       

        

       

        

      INGERSOLL-RAND PUBLIC LIMITED COMPANY

      REGISTERED OFFICE: 170/175 LAKEVIEW DRIVE, SWORDS, DUBLIN IRELAND 

      REGISTERED IN IRELAND WITH LIMITED LIABILITY REGISTERED NUMBER: 469272

      DIRECTORS: K.E. ARNOLD (U.S.A.), A.C. BERZIN (U.S.A.), J. BRUTON. J L. COHON (U.S.A.), G.D. FORSEE (U.S.A.),

      L.P. HUDSON (U.S.A.), M.W. LAMACH (U.S.A.), M.P. LEE, K.B.
          PEETZ (U S.A.), J.P. SURMA (US.A.), R.J. SWIFT (US.A.), T.L WHITE (U.S.A.)

      

      

      
        
          

      

      
      
        	Mr. Chris Kuehn

              	
                December 5, 2019 

                

              

      

      

      

      

      

      
        
          
            
              
                	 	

                      	
                        made in an equal proportion of stock options and RSUs. The award value will be converted into stock options and RSUs based on the fair market value of Ingersoll Rand's ordinary shares on the date the Compensation Committee of
                          the Board of Directors (“the Committee”) approves the awards. Stock option and RSU awards generally vest ratably, one-third each year, over three years from the date of grant. Annual equity awards are contingent on and variable
                          with your sustained performance and demonstrated leadership potential. 

                      

              

               

            

          

        

      

      
        
          
            	 	
                    ●

                  	
                    Performance Share Unit (“PSUs”): Your annual grant target under the Company's Performance Share Program (“PSP”) will increase from $325,000 to $900,000 or by $575,000. At
                      this time, based on the projected transaction close date of March 2nd, it is anticipated that your updated equity target will be used to determine your
                      award in 2020 and the target award value will be converted into PSUs based on the fair market value of Ingersoll Rand's ordinary shares on the date the Committee approves the award. PSUs are based on performance over a three-year
                      period and settled in ordinary shares of the Company. At this time, the actual number of PSUs earned will be based on Ingersoll Rand’s Cash Flow Return on Invested Capital (“CROIC”) and Total Shareholder Return (“TSR”), both relative
                      to the S&P 500 Industrials Index over the 2020 to 2022 performance period and can range from 0% to 200% of the target number of PSUs. PSP performance goals are subject to change for future performance periods at the discretion of
                      the Committee.

                  

          

        

      

      

      
        
          
            
              
                
                  
                    	 	

                          	
                            Your minimum level of required share ownership will increase from 15,000 to 30,000 ordinary shares of the Company. You must achieve this increased ownership requirement within a five-year period from the Effective Date of
                              this role. 

                          

                  

                   

                

              

            

          

        

      

      When you consider each of the items above, your Total Annual Direct Compensation target has increased from $1,491,500 to $3,160,000 or by $1,668,500
        (111.9%). Your revised compensation is summarized in the attached Compensation Adjustment Notice.

      

      

      
        
          
            
              	
                      4.

                    	
                      You will be provided with a Change in Control Agreement (“CIC Agreement”), which provides economic security in the form of cash payments to the participant and enhanced coverage under certain benefit plans in the event of job
                        loss caused by the sale of all or a substantial part of the Company. Your severance payment under a Change in Control (as defined in the CIC Agreement) would be equal to 2.5 times your base salary plus your AIM. The actual agreement
                        will be sent to you shortly after you assume this new role.

                    

            

          

        

      

      

      

      
        
          
            
              	
                      5.

                    	
                      You will continue to be eligible to participate in the following programs:

                    

            

          

        

      

      
        
          
            
              	 	
                      a.

                    	
                      Executive Deferred Compensation Plan

                    

            

          

        

      

      
        
          
            
              	 	
                      b.

                    	
                      Executive Health Program

                    

            

          

        

      

      
        
          
            
              	 	
                      c.

                    	
                      Executive Long Term Disability (“LTD”) Plan

                    

            

          

        

      

      
        
          
            
              	 	
                      d.

                    	
                      Financial Counseling Program

                    

            

          

        

      

      
        
          
            
              	 	
                      e.

                    	
                      All employee benefit programs offered to Ingersoll Rand US based salaried employees in accordance with the terms and conditions of these programs

                    

            

          

        

      

      

      

      

      

      
        2

        
          

      

      
        
          	Mr. Chris Kuehn

                	
                  December 5, 2019 

                  

                

        

        

        

      

      

      

      Chris, we believe that you will make a significant contribution in this expanded role. To accept this offer, please sign the
        candidate acceptance below and return it to Lynn Castrataro, Vice President, Total Rewards. The Non-Competition Agreement that you signed on May 7, 2015 remains in effect. In addition, the Proprietary Agreement you executed online at an earlier
        date also remains in force. If you have any questions regarding the changes in your compensation or your benefits, please call Lynn at 704-990-3633.

      

      

      

      

      Sincerely,

       

      

       

       

      

      Michael W. Lamach

      Chairman and Chief Executive Officer

      

      

      
        	
                cc:

              	
                Marcia Avedon

                Lynn Castrataro 

              

      

      

      

      

      

      

      

      CANDIDATE  ACCEPTANCE

       

      

       

      

      I accept your offer of employment with Ingersoll Rand as Senior Vice President and Chief Financial Officer and agree to the conditions herein and in
        the offer letter.

       

      

       
        

        

        

        

        3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]